Calliditas reports strong fourth-quarter growth, targets future expansion
[ad_1]
©Reuters. STOCKHOLM – Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX), a biopharmaceutical company specializing in rare diseases, reported significant revenue growth in the fourth quarter, with preliminary net sales of its TARPEYO product rising from $31 million. to $33 million. This is a significant increase compared to the third quarter. The company also announced preliminary TARPEYO net revenue for the full year 2023, reaching $100 million to $102 million, an increase of more than 170% from 2022.
Total revenue in 2023 is expected to be $110 million to $113 million, driven by milestone payments and royalty revenue from Nefecon franchises outside the United States. Patient registrations also hit a record high in the fourth quarter, with 555 new prescriptions for TARPEYO.
These preliminary results reflect estimates based on currently available information and may change upon completion of financial close.
Calliditas CEO Renée Aguiar-Lucander credited TARPEYO’s full U.S. approval, enhanced product protections and record fourth-quarter enrollment as key factors that put the company in a strong position to drive growth and profitability through 2024.
The information provided is based on press release statements and reflects Calliditas’ current expectations.
This article was created and translated with the help of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.
